These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35119780)

  • 1. Structural insights into the substrate-binding site of main protease for the structure-based COVID-19 drug discovery.
    Firouzi R; Ashouri M; Karimi-Jafari MH
    Proteins; 2022 May; 90(5):1090-1101. PubMed ID: 35119780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
    Purohit P; Dash JJ; Muya JT; Meher BR
    J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease.
    de Oliveira Só YA; Bezerra KS; Gargano R; Mendonça FLL; Souto JT; Fulco UL; Pereira Junior ML; Junior LAR
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
    de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
    Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
    Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
    J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations.
    Singh R; Bhardwaj VK; Das P; Bhattacherjee D; Zyryanov GV; Purohit R
    Comput Biol Med; 2022 Jul; 146():105572. PubMed ID: 35551011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into SARS-CoV-2 main protease conformational plasticity.
    Dehury B; Mishra S; Pati S
    J Cell Biochem; 2023 Jun; 124(6):861-876. PubMed ID: 37099673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
    Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
    Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
    Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
    Mol Divers; 2021 Aug; 25(3):1745-1759. PubMed ID: 33236176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
    Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
    Rehman MT; AlAjmi MF; Hussain A
    Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
    Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
    J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.